Digipath
Home > Boards > US Listed > Biotechs >

Immune Design Corp. (IMDZ)

IMDZ RSS Feed
Add IMDZ Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/7/2018 3:11:24 PM - Followers: 8 - Board type: Free - Posts Today: 0

Immune Design Corp. 1616 Eastlake Avenue East Suite 310 Seattle, WA 98102 United States Phone: 206-682-0645 Fax: 206-682-0648 Website: http://www.immunedesign.com Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The companys oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage for the treatment of non-Hodgkin lymphoma. It also develops therapies for non-oncology diseases, including infectious diseases, allergy, and autoimmune diseases. The company has license agreements with the California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; collaboration agreements with Sanofi Pasteur, Merck & Co., Inc., and Genentech. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington with additional facilities in South San Francisco, California.
Digipath
IMDZ
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMDZ News: Current Report Filing (8-k) 12/10/2018 06:09:05 AM
IMDZ News: Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lympho... 12/02/2018 12:00:00 PM
IMDZ News: Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference 11/20/2018 08:00:00 AM
IMDZ News: Current Report Filing (8-k) 11/13/2018 04:52:31 PM
IMDZ News: Initial Statement of Beneficial Ownership (3) 11/09/2018 06:28:42 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#59   Up 50% now, in a sea of red Dream_Weaving 12/07/18 03:11:24 PM
#58   Yawn, up 40% now and this is about Dream_Weaving 12/04/18 10:05:11 AM
#57   Today is payday from low 1.30s, too bad Dream_Weaving 12/04/18 09:49:04 AM
#56   holding overnight aristotelisonassis 12/03/18 04:05:03 PM
#55   Looking marvelous from those low 1.34s just days ago..... Dream_Weaving 12/03/18 03:18:45 PM
#54   yet another huge score for me. Dream_Weaving 12/03/18 10:29:21 AM
#53   But if you notice, I only "dropped by" Dream_Weaving 12/02/18 05:45:14 PM
#52   I drop by and I'm sure a few jondoeuk 12/02/18 03:47:35 PM
#51   Yawn, why did no one else buy with Dream_Weaving 11/30/18 01:51:01 PM
#50   Do you not understand when I say it Dream_Weaving 11/30/18 10:08:47 AM
#49   jiggy time. Dream_Weaving 11/29/18 02:58:19 PM
#48   Am I the only one here? Dream_Weaving 11/28/18 12:31:46 PM
#47   ASH abstract https://ash.confex.com/ash/2018/webprogram/Paper117932.html jondoeuk 11/03/18 06:30:24 PM
#46   and Jam. I made 17% profit during pre-market PennyWorld 10/14/18 03:01:48 PM
#45   Toast 420man 10/13/18 08:56:20 AM
#44   ... Phase 2 study that showed the combination willlbone 10/12/18 09:54:26 AM
#43   Immune Design Nearing Critical Point In Valuation stockguard 05/15/18 04:42:50 PM
#42   https://charts.stocktwits.com/production/original_123535328.png stockguard 05/15/18 04:16:11 PM
#41   MoMo algo`s going to kick in. Breaking out stockguard 05/15/18 04:03:11 PM
#40   Immune Design Reports Data Update for Lead Immunotherapy chmcnfunds 03/12/18 08:59:35 AM
#39   Looks like it's heavily shorted. But still a QServus 11/14/17 09:47:09 AM
#38   Looks like the Dumping has stopped to me! DTGoody 11/08/17 02:50:14 PM
#37   It's going to run when dumping is done QServus 11/02/17 02:05:44 PM
#36   All these insiders buying shares kind of make DTGoody 11/02/17 09:31:12 AM
#35   Probably going to slowly bleed until next quarter. willlbone 10/24/17 03:42:32 PM
#34   Going to $3 - reload then QServus 10/24/17 01:09:43 PM
#33   Dilution and drug failure willlbone 10/24/17 12:55:17 PM
#32   Very! QServus 10/23/17 11:55:26 AM
#31   Bullish !! Chuckx 10/23/17 04:57:53 AM
#30   Churning at 5.20 like mad - crazy run QServus 10/20/17 03:53:54 PM
#29   Looks like bottom is in QServus 10/20/17 01:10:13 PM
#28   Break that resistance @ 6 and off to QServus 10/20/17 07:42:30 AM
#27   RBC upper their target on this from $20 QServus 10/19/17 08:46:05 PM
#26   Yea but $6 is almost hitting now after market QServus 10/19/17 04:52:35 PM
#25   Down 6 days in a row -50% shurtha2000 10/19/17 04:50:06 PM
#24   We can definitely close 6.50-7 tomorrow QServus 10/19/17 04:49:13 PM
#23   Yep, why did it drop in first place lol QServus 10/19/17 04:43:45 PM
#22   Stuck at $5.60 AH's should bounce tomorrow shurtha2000 10/19/17 04:33:38 PM
#21   Huge news out we gap up tomorrow wow QServus 10/19/17 04:07:15 PM
#20   I think we'll have a good bounce tomorrow QServus 10/19/17 03:37:17 PM
#19   Why did it drop so quick ? I QServus 10/19/17 03:09:43 PM
#18   I had to get out. Pushed my comfort Bleederhead 10/19/17 02:54:45 PM
#17   What's the scoop why the big drop QServus 10/19/17 02:52:10 PM
#16   Seems like rock bottom opportunity here QServus 10/19/17 02:51:58 PM
#15   I'm in for this upcoming ride. Glta Bleederhead 10/17/17 04:30:21 PM
#14   BROOKSIDE CAPITAL MANAGEMENT LLC has filed a new wiltonio 10/06/17 04:17:37 PM
#13   Immune Design (NASDAQ:IMDZ) initiated with Outperform rating and Avispa 08/24/17 08:16:01 AM
#12   Charts show a move to $22 biotechnician 06/27/17 08:16:57 AM
#11   IMDZ bearish 8.30 stocktrademan 11/13/16 04:31:05 PM
#10   The webcast for the second quarter financial results jondoeuk 08/05/16 06:49:27 AM
PostSubject